JP7063915B2 - Ｉｐ６ｋ阻害剤 - Google Patents

Ｉｐ６ｋ阻害剤 Download PDF

Info

Publication number
JP7063915B2
JP7063915B2 JP2019554003A JP2019554003A JP7063915B2 JP 7063915 B2 JP7063915 B2 JP 7063915B2 JP 2019554003 A JP2019554003 A JP 2019554003A JP 2019554003 A JP2019554003 A JP 2019554003A JP 7063915 B2 JP7063915 B2 JP 7063915B2
Authority
JP
Japan
Prior art keywords
group
compound
cyclohexane
dihydrospiro
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019554003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515620A5 (https=
JP2020515620A (ja
Inventor
嘉人 寺尾
昌志 高橋
亮磨 原
功介 日▲高▼
英紀 古川
健 山▲崎▼
静夫 河西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62134158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7063915(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2020515620A publication Critical patent/JP2020515620A/ja
Publication of JP2020515620A5 publication Critical patent/JP2020515620A5/ja
Application granted granted Critical
Publication of JP7063915B2 publication Critical patent/JP7063915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2019554003A 2017-03-30 2018-03-29 Ｉｐ６ｋ阻害剤 Active JP7063915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017066579 2017-03-30
JP2017066579 2017-03-30
PCT/JP2018/014502 WO2018182051A1 (en) 2017-03-30 2018-03-29 Ip6k inhibitors

Publications (3)

Publication Number Publication Date
JP2020515620A JP2020515620A (ja) 2020-05-28
JP2020515620A5 JP2020515620A5 (https=) 2021-05-06
JP7063915B2 true JP7063915B2 (ja) 2022-05-09

Family

ID=62134158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019554003A Active JP7063915B2 (ja) 2017-03-30 2018-03-29 Ｉｐ６ｋ阻害剤

Country Status (24)

Country Link
US (1) US10968178B2 (https=)
EP (1) EP3601256A1 (https=)
JP (1) JP7063915B2 (https=)
KR (1) KR102597117B1 (https=)
CN (1) CN110461828B (https=)
AR (1) AR111307A1 (https=)
AU (1) AU2018246053B2 (https=)
CA (1) CA3057821A1 (https=)
CL (1) CL2019002662A1 (https=)
CO (1) CO2019012125A2 (https=)
EA (1) EA038177B1 (https=)
EC (1) ECSP19077969A (https=)
IL (1) IL269347B2 (https=)
JO (1) JOP20180029A1 (https=)
MA (1) MA49006A (https=)
MX (1) MX393896B (https=)
NZ (1) NZ758061A (https=)
PE (1) PE20191656A1 (https=)
PH (1) PH12019502248A1 (https=)
SG (1) SG11201908894SA (https=)
TW (1) TWI778038B (https=)
UA (1) UA125445C2 (https=)
WO (1) WO2018182051A1 (https=)
ZA (1) ZA201907136B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110214012B (zh) 2017-01-20 2023-05-09 艾库斯生物科学有限公司 用于治疗癌症相关疾病的唑嘧啶
RU2019133646A (ru) 2017-03-30 2021-04-30 Ф. Хоффманн-Ля Рош Аг Изохинолины в качестве ингибиторов hpk1
CA3090922A1 (en) 2018-02-16 2019-08-22 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
CN112601584A (zh) 2018-07-24 2021-04-02 豪夫迈·罗氏有限公司 异喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
US20230183234A1 (en) * 2020-05-04 2023-06-15 Otsuka Pharmaceutical Co., Ltd. Iap antagonist compounds and intermediates and methods for synthesizing the same
UY39609A (es) * 2021-01-12 2022-08-31 Servier Lab Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos
WO2023154466A1 (en) * 2022-02-11 2023-08-17 The University Of North Carolina At Chapel Hill Arylbenzoisoxazole compounds as ip6k and ipmk inhibitors and methods of use thereof
CN115747325A (zh) * 2022-11-10 2023-03-07 上海交通大学医学院附属新华医院 Ip6k1及其产物作为增加血液脂联素药物靶点的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510598A (ja) 2002-09-24 2006-03-30 トゥラリック インコーポレイテッド ピペリジン誘導体
JP2011516512A (ja) 2008-04-11 2011-05-26 アルミラル・ソシエダッド・アノニマ 新規な置換スピロ［シクロアルキル−１，３’−インドール］−２’（１’ｈ）−オン誘導体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
NZ540381A (en) 2002-11-01 2007-11-30 Takeda Pharmaceutical 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
EP1698624B1 (en) 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
KR20080033524A (ko) 2005-08-10 2008-04-16 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료제
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
BRPI0713378A8 (pt) 2006-06-27 2018-01-02 Takeda Pharmaceutical composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto
EP2077267A4 (en) 2006-10-18 2010-04-07 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
US7652133B2 (en) 2006-10-19 2010-01-26 Takeda Pharmaceutical Company Limited Indole compound
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
EP2118066A1 (en) 2007-02-09 2009-11-18 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
RU2019133646A (ru) 2017-03-30 2021-04-30 Ф. Хоффманн-Ля Рош Аг Изохинолины в качестве ингибиторов hpk1
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510598A (ja) 2002-09-24 2006-03-30 トゥラリック インコーポレイテッド ピペリジン誘導体
JP2011516512A (ja) 2008-04-11 2011-05-26 アルミラル・ソシエダッド・アノニマ 新規な置換スピロ［シクロアルキル−１，３’−インドール］−２’（１’ｈ）−オン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF BIOLOGICAL CHEMISTRY，2009年04月17日，Vol. 284, No. 16，pp. 10571-10582

Also Published As

Publication number Publication date
AR111307A1 (es) 2019-06-26
MX2019011783A (es) 2020-02-10
UA125445C2 (uk) 2022-03-09
TW201840534A (zh) 2018-11-16
WO2018182051A8 (en) 2019-04-11
WO2018182051A1 (en) 2018-10-04
SG11201908894SA (en) 2019-10-30
US20200377458A1 (en) 2020-12-03
AU2018246053A1 (en) 2019-11-14
PH12019502248A1 (en) 2020-06-29
MA49006A (fr) 2020-02-05
EP3601256A1 (en) 2020-02-05
KR20190134676A (ko) 2019-12-04
ECSP19077969A (es) 2020-02-28
CO2019012125A2 (es) 2020-01-17
ZA201907136B (en) 2021-07-28
IL269347A (en) 2019-11-28
AU2018246053A8 (en) 2019-11-21
PE20191656A1 (es) 2019-11-07
CA3057821A1 (en) 2018-10-04
JP2020515620A (ja) 2020-05-28
IL269347B (en) 2022-12-01
AU2018246053B2 (en) 2022-02-17
KR102597117B1 (ko) 2023-11-01
CL2019002662A1 (es) 2020-01-24
US10968178B2 (en) 2021-04-06
JOP20180029A1 (ar) 2019-01-30
TWI778038B (zh) 2022-09-21
IL269347B2 (en) 2023-04-01
CN110461828B (zh) 2022-07-19
NZ758061A (en) 2026-02-27
BR112019020194A2 (pt) 2020-04-22
EA201992306A1 (ru) 2020-02-20
MX393896B (es) 2025-03-19
CN110461828A (zh) 2019-11-15
EA038177B1 (ru) 2021-07-20

Similar Documents

Publication Publication Date Title
JP7063915B2 (ja) Ｉｐ６ｋ阻害剤
JP6788683B2 (ja) 複素環化合物
JPWO2020004536A1 (ja) 複素環化合物およびその用途
JPWO2020122093A1 (ja) 複素環化合物
JP6411520B2 (ja) 複素環化合物
JPWO2019065791A1 (ja) 複素環化合物
WO2021106975A1 (ja) 複素環化合物
JP6450755B2 (ja) 複素環化合物
JP2022064180A (ja) 複素環化合物
JPWO2020153414A1 (ja) 複素環化合物及びその用途
JP2021080177A (ja) 複素環化合物及びその用途
JPWO2019070043A1 (ja) 複素環化合物
JPWO2020067455A1 (ja) 複素環化合物
JP2021519294A (ja) 複素環化合物及びその用途
WO2020196828A1 (ja) 含窒素複素環化合物
JP2021183587A (ja) 複素環化合物
JP7177042B2 (ja) 複素環化合物
BR112019020194B1 (pt) Compostos, medicamento, e, uso do composto
JPWO2020067456A1 (ja) 複素環化合物
JPWO2020067457A1 (ja) 縮合環化合物
JP2021050161A (ja) 複素環化合物及びその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220421

R150 Certificate of patent or registration of utility model

Ref document number: 7063915

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250